Skip to content

BPC-157 for Erectile Dysfunction: What the Research Says

BPC-157 for erectile dysfunction: zero published studies, in humans or animals. What BPC-157's real evidence covers, and what is actually FDA-approved for ED.

Sebastian Hunter, Founder and EditorWritten bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

The short version

No study, in animals or humans, tests BPC-157 for erectile dysfunction: a direct PubMed search returns zero results. BPC-157's real evidence is in unrelated areas: gut healing, tendon repair, one small urinary-incontinence rat study, and a handful of small human studies with no sexual-function outcome. PDE5 inhibitors like sildenafil are FDA-approved for erectile dysfunction. PT-141 (bremelanotide) is a different peptide, FDA-approved only for low sexual desire in premenopausal women, not for men or for erectile function.

  • Zero published studies test BPC-157 for erectile dysfunction, in humans or animals, per a direct PubMed search.
  • BPC-157's actual human evidence, a handful of small studies, does not touch sexual or erectile function at all.
  • PDE5 inhibitors (sildenafil and others) are FDA-approved specifically for erectile dysfunction.
  • PT-141 (bremelanotide) is FDA-approved, but for hypoactive sexual desire in premenopausal women, not for men or for erectile dysfunction.

Zero published studies test BPC-157 for erectile dysfunction, in humans or animals. A direct PubMed search combining BPC-157 with erectile, penile and erection terms returns nothing on point. That is rarer than weak evidence. For most uses BPC-157 is sold for, some rodent data exists even where human data does not. For erectile dysfunction, this page could not find a study of any kind. Erectile dysfunction already has FDA-approved treatment, and this page reports the empty search result rather than implying a peptide fills a gap.

Does BPC-157 help erectile dysfunction?

No study answers this question, because no study asked it. Searching PubMed for BPC-157 together with “erectile” returns zero records. Broadening the search to libido, sexual behavior, testosterone and cavernosum (the erectile tissue PDE5 inhibitors act on) still returns nothing on point. As far as the searchable literature shows, nobody has tested BPC-157 for erectile function in a rat, a dog or a person.

What BPC-157’s actual evidence covers (and doesn’t)

BPC-157’s real research base is elsewhere. It includes:

Full detail on what BPC-157 has and has not been shown to do: BPC-157.

PT-141 (bremelanotide): approved, but not for this

Some sexual-health marketing compares PT-141 to BPC-157, but PT-141 is a different peptide with a different, approved use. Bremelanotide, sold as Vyleesi, is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder. That is a low-desire condition, not erectile dysfunction Kingsberg 2019 - Kingsberg SA, Clayton AH, Portman D et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908., in the references below. Older randomized trials tested it in men who had not responded to sildenafil. That line of development never led to an approval for men or for erectile dysfunction specifically. Full detail: PT-141.

What is actually approved for erectile dysfunction

Phosphodiesterase-5 (PDE5) inhibitors are FDA-approved specifically for erectile dysfunction. Sildenafil’s own FDA label states it is indicated for the treatment of erectile dysfunction (ED). That approval rests on a verified mechanism (increased blood flow to erectile tissue) and a completed clinical trial programme. Neither BPC-157 nor PT-141 has that for this condition.

Common questions

Is there any research on BPC-157 for ED?

No. BPC-157's published research covers gastrointestinal healing, tendon and ligament injury, and a rat study of stress urinary incontinence. That is a different genitourinary condition, in female rats, and unrelated to erectile function. Its human evidence is a handful of very small studies (interstitial cystitis, knee pain, an unpublished ulcerative colitis trial). None measured sexual or erectile function.

What is FDA-approved for erectile dysfunction?

Phosphodiesterase-5 (PDE5) inhibitors are FDA-approved specifically for erectile dysfunction. Sildenafil's own FDA label states it is indicated for the treatment of erectile dysfunction (ED). That is an approved drug class working through a verified mechanism (increasing blood flow), not a research chemical with no ED-specific study behind it.

Is PT-141 approved for erectile dysfunction in men?

No. PT-141 (bremelanotide) is FDA-approved, as Vyleesi, for premenopausal women with acquired, generalized hypoactive sexual desire disorder. That is a low-desire condition, not erectile dysfunction, and not in men. Older randomized trials tested it in men who had not responded to sildenafil. That line of development did not lead to an approval for men or for erectile dysfunction specifically.

Is BPC-157 safe to use for sexual performance?

No safety data exists for this use, because no study has tested BPC-157 for sexual or erectile function. Separately, BPC-157 has no long-term human safety data for any use, is not FDA-approved, and is prohibited at all times in sport. Buying it for a use with zero research behind it adds an efficacy unknown on top of the safety unknowns that apply to every use of BPC-157.

References (6 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

  1. 1.Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2).ReviewPMID 40005999full text
  2. 2.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.ReviewPMID 30915550
  3. 3.Kingsberg SA, Clayton AH, Portman D et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.Randomised trialPMID 31599840full text
  4. 4.Jandric I, Vrcic H, Jandric Balen M et al. Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats. Med Sci Monit Basic Res. 2013;19:93-102.StudyPMID 23478678full text
  5. 5.FDA label (DailyMed) for sildenafil citrate tablets - indicated for the treatment of erectile dysfunction (ED). Fetched this session.- DailyMed, US National Library of Medicinelabel
  6. 6.NCBI E-utilities esearch: BPC-157 AND (erectile OR "erectile dysfunction" OR penile), zero results for erectile-specific terms; a broader libido/sexual/testosterone/cavernosum search also returns nothing on point (queried 2026-09-27).- National Center for Biotechnology Information, US National Library of Medicinedatabase

Keep reading

Related guides